X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
immuno-oncology (271) 271
immunotherapy (129) 129
oncology (119) 119
index medicus (107) 107
cancer (104) 104
humans (84) 84
immunology (38) 38
tumors (38) 38
melanoma (37) 37
animals (31) 31
nivolumab (31) 31
chemotherapy (29) 29
neoplasms - immunology (29) 29
pharmacology & pharmacy (29) 29
clinical trials (27) 27
immunotherapy - methods (27) 27
ipilimumab (27) 27
review (26) 26
biomarkers (24) 24
therapy (23) 23
cancer therapies (21) 21
pembrolizumab (21) 21
analysis (20) 20
care and treatment (20) 20
cell lung-cancer (20) 20
immune checkpoint (20) 20
immune response (20) 20
neoplasms - therapy (20) 20
open-label (20) 20
patients (20) 20
pd-1 (20) 20
research (20) 20
expression (19) 19
t cells (19) 19
cancer immunotherapy (18) 18
medicine & public health (18) 18
pd-l1 (18) 18
antigens (17) 17
antineoplastic agents - therapeutic use (17) 17
lung cancer (17) 17
metastasis (17) 17
gene expression (16) 16
lymphocytes t (16) 16
t-cells (16) 16
apoptosis (15) 15
checkpoint inhibitors (15) 15
chemistry, medicinal (15) 15
female (15) 15
immune system (15) 15
lymphocytes (15) 15
medical research (15) 15
metastatic melanoma (15) 15
mice (15) 15
neoplasms - drug therapy (15) 15
precision medicine (15) 15
survival (15) 15
tumor microenvironment (15) 15
cancer-immunotherapy (14) 14
health aspects (14) 14
male (14) 14
medicine, research & experimental (14) 14
neoplasms. tumors. oncology. including cancer and carcinogens (14) 14
regulatory t-cells (14) 14
usage (14) 14
metastases (13) 13
pd-1 blockade (13) 13
programmed cell death 1 receptor - antagonists & inhibitors (13) 13
solid tumors (13) 13
cell death (12) 12
ctla-4 (12) 12
immune checkpoint inhibitor (12) 12
immuno‐oncology (12) 12
monoclonal antibodies (12) 12
advanced melanoma (11) 11
antibodies (11) 11
antibody (11) 11
antitumor immunity (11) 11
blockade (11) 11
cancer research (11) 11
dendritic cells (11) 11
fda approval (11) 11
immunohistochemistry (11) 11
middle aged (11) 11
molecular targeted therapy (11) 11
pd-l1 protein (11) 11
aged (10) 10
cytotoxicity (10) 10
genetic aspects (10) 10
hematology (10) 10
immune checkpoint blockade (10) 10
indoleamine 2,3-dioxygenase (10) 10
kinases (10) 10
mutation (10) 10
neoplasms - pathology (10) 10
pharmacology (10) 10
prognosis (10) 10
vaccines (10) 10
antibodies, monoclonal - therapeutic use (9) 9
cells (9) 9
double-blind (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


ACS Medicinal Chemistry Letters, ISSN 1948-5875, 05/2017, Volume 8, Issue 5, pp. 486 - 491
A data-centric medicinal chemistry approach led to the invention of a potent and selective IDO1 inhibitor , INCB24360 (epacadostat). The molecular structure of... 
Epacadostat | data-centric medicinal chemistry | immuno-oncology | INCB24360 | IDO1
Journal Article
OncoImmunology, ISSN 2162-402X, 08/2019, Volume 8, Issue 8, p. 1599635
In vitro assays that evaluate CD8 + T cell-mediated cytotoxicity are important to aid in the development of novel therapeutic approaches to enhance anti-tumor... 
immuno-oncology | T cell | cytotoxicity | immunotherapy
Journal Article
Methods in Enzymology, ISSN 0076-6879, 2019
Emergency of the CRISPR technology, a new genome editing tool, revolutionized the biomedical research field in the past 6 years. At the same time, recent... 
CRISPR | CAR-T | sgRNA | Immunotherapy | dCas9 | Cas9 | Immuno-oncology | Cancer
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2018, Volume 29, Issue 11, pp. 2208 - 2213
Abstract Background A nivolumab monotherapy flat-dosing regimen of 480 mg every 4 weeks (Q4W) has been approved in several markets, including the United... 
PK exposure | Safety | Solid tumors | Q4W | Immuno-oncology | Nivolumab | nivolumab | ONCOLOGY | safety | immuno-oncology | CELL | DOCETAXEL | solid tumors | CHEMOTHERAPY | Life Sciences | Original
Journal Article
OncoImmunology, ISSN 2162-4011, 04/2018, p. e1343774
Journal Article
Annals of Oncology, ISSN 0923-7534, 12/2017, Volume 28, Issue 12, pp. 2977 - 2984
Background: Novel immune checkpoint blockade strategies are being evaluated in clinical trials and include targeting the lymphocyte activation gene 3 (LAG-3)... 
Immunohistochemistry | Breast cancer | Immune checkpoints | LAG-3 | Immuno-oncology | ONCOLOGY | ESTROGEN | breast cancer | ANTIBODY | immuno-oncology | immunohistochemistry | immune checkpoints | Index Medicus
Journal Article
Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 07/2018, Volume 143, Issue 14, pp. 1022 - 1029
Journal Article
Expert Opinion on Therapeutic Patents, ISSN 1354-3776, 08/2019, Volume 29, Issue 8, pp. 587 - 593
Introduction: TIM3 and PD-1 are checkpoint inhibitors in cancer that coordinate the downregulation of the proliferation of antigen-specific lymphocytes. There... 
checkpoint | immuno-oncology | patent | TIM3 | bispecific antibodies | PD-1 | Index Medicus
Journal Article
Expert Opinion on Therapeutic Patents, ISSN 1354-3776, 08/2019, Volume 29, Issue 8, pp. 643 - 651
Introduction: LAG-3 is checkpoint inhibitor in cancer that coordinates the downregulation of the proliferation of antigen-specific lymphocytes. There is a... 
checkpoint | cancer | immuno-oncology | patent | LAG-3 | immunotherapy | Index Medicus
Journal Article
Oncotarget, ISSN 1949-2553, 01/2019, Volume 10, Issue 2, pp. 209 - 215
Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) mutation benefit from a first line of treatment with tyrosine kinase... 
EGFR mutation | Chemotherapy | NSCLC | Immuno-oncology | Immunotherapy
Journal Article
Journal of Hepatology, ISSN 0168-8278, 09/2019, Volume 71, Issue 3, pp. 543 - 552
Nivolumab, an immune checkpoint inhibitor, is approved in several countries to treat sorafenib-experienced patients with HCC, based on results from the... 
Liver cancer | Nivolumab | HCC | Hepatocellular carcinoma | PD-1 inhibitor | Immuno-oncology | Asian | CheckMate
Journal Article
Statistics in Medicine, ISSN 0277-6715, 09/2019, Volume 38, Issue 20, pp. 3782 - 3790
We propose a new class of weighted logrank tests (WLRTs) that control the risk of concluding that a new drug is more efficacious than standard of care, when,... 
drug regulation | immuno‐oncology | weighted logrank test | nonproportional hazards | Index Medicus
Journal Article
Neuro-Oncology, ISSN 1522-8517, 09/2018, Volume 20, Issue 10, pp. 1383 - 1392
Abstract Background Vocimagene amiretrorepvec (Toca 511) is an investigational gamma-retroviral replicating vector encoding cytosine deaminase that, when used... 
Recurrent high grade glioma | Durable response rate | Gene therapy | Immuno-oncology | Immunotherapy
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2018, Volume 13, Issue 11, pp. 1771 - 1775
Introduction: Checkpoint inhibitors augment the immune system's natural surveillance mechanisms and have increasing applications in NSCLC. Immunosuppressive... 
immuno-oncology | corticosteroids | nivolumab | NSCLC | CELL LUNG-CANCER | ONCOLOGY | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article
Oncotarget, ISSN 1949-2553, 2018, Volume 9, Issue 17, pp. 13593 - 13611
The adenosine receptor (AR) subtypes A2A and A2B are rhodopsin-like Gs protein-coupled receptors whose expression is highly regulated under pathological, e.g.... 
Receptor heteromerization | G protein-coupled receptor (GPCR) | Adenosine receptors (ARs) | Pharmacology | Immuno-oncology
Journal Article
Experimental biology and medicine (Maywood, N.J.), ISSN 1535-3702, 06/2019, pp. 1535370219855970 - 1535370219855970
Journal Article
by Thorsson, Vesteinn and Thorsson, Vésteinn and Gibbs, Richard A and Gibbs, David L and Brown, Scott D and Wolf, Gregory and Wolf, Denise and Bortone, Dante S and Ou Yang, Tai-Hsien and Porta-Pardo, Eduard and Gao, Galen F and Gao, Jianjiong and Plaisier, Christopher L and Eddy, James A and Ziv, Elad and Culhane, Aedin C and Paull, Evan O and Sivakumar, I.K. Ashok and Gentles, Andrew J and Malhotra, Raunaq and Farshidfar, Farshad and Colaprico, Antonio and Parker, Joel S and Mose, Lisle E and Vo, Nam Sy and Liu, Wenbin and Liu, Jianfang and Liu, Jia and Liu, Yuexin and Liu, Xiuping and Rader, Janet and Dhankani, Varsha and Reynolds, Sheila and Reynolds, Sheila M and Bowlby, Reanne and Califano, Andrea and Cherniack, Andrew D and Anastassiou, Dimitris and Bedognetti, Davide and Rao, Arvind and Chen, Chu and Chen, Ken and Chen, Amy and Krasnitz, Alexander and Hu, Jianhong and Hu, Hai and Malta, Tathiane M and Noushmehr, Houtan and Pedamallu, Chandra Sekhar and Bullman, Susan and Ojesina, Akinyemi I and Lamb, Andrew and Zhou, Wanding and Shen, Hui and Choueiri, Toni K and Weinstein, John N and Guinney, Justin and Saltz, Joel and Holt, Robert and Holt, Robert A and Rabkin, Charles E and Caesar-Johnson, Samantha J and Demchok, John A and Felau, Ina and Kasapi, Melpomeni and Ferguson, Martin L and Hutter, Carolyn M and Sofia, Heidi J and Tarnuzzer, Roy and Wang, Jioajiao and Wang, Linghua and Wang, Zhining and Wang, Jing and Wang, Timothy and Wang, Min and Yang, Hannah and Yang, Ian and Yang, Ju Dong and Yang, Liming and Zenklusen, Jean C and Zhang, Lizhi and Zhang, Hongxin and Zhang, Jiexin and Zhang, Hongzheng and Zhang, Jiashan (Julia) and Zhang, Wei and Zhang, Hailei and Chudamani, Sudha and Lolla, Laxmi and Naresh, Rashi and Pihl, Todd and Sun, Yichao and Sun, Qiang and Wan, Yunhu and Wu, Ye and Cho, Juok and DeFreitas, Timothy and Frazer, Scott and Gehlenborg, Nils and Getz, Gad and ... and Canc Genome Atlas Res Network and Cancer Genome Atlas Research Network
Immunity, ISSN 1074-7613, 04/2018, Volume 48, Issue 4, pp. 812 - 830.e14
We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising 33 diverse cancer types by utilizing data compiled by TCGA. Across... 
tumor immunology | immunotherapy | cancer genomics | integrative network analysis | immuno-oncology | tumor microenvironment | immune subtypes | immunomodulatory | GENOMIC ANALYSES | INFORMATION | T-CELL-RECEPTOR | REGULATORY NETWORK | CLASSIFICATION | IMMUNOLOGY | SEQUENCING DATA | SOMATIC MUTATIONS | COMPREHENSIVE ANALYSIS | PREDICTION | REVEALS | Transforming Growth Factor beta - immunology | Prognosis | Humans | Middle Aged | Th1-Th2 Balance - physiology | Male | Neoplasms - classification | Wound Healing - immunology | Young Adult | Transforming Growth Factor beta - genetics | Neoplasms - genetics | Neoplasms - immunology | Interferon-gamma - immunology | Adolescent | Aged, 80 and over | Adult | Female | Aged | Interferon-gamma - genetics | Wound Healing - genetics | Genomics - methods | Child | Macrophages - immunology | Cell proliferation | Cluster analysis | Transcription | Copy number | p53 Protein | Lung cancer | Genomics | Aneuploidy | Lymphocytes T | Genomes | Cell interactions | Macrophages | Immunotherapy | DNA methylation | Deoxyribonucleic acid--DNA | Immune system | Medical research | Wound healing | Immunomodulation | MiRNA | Stockholders | Inflammation | T cell receptors | Communications networks | Gene expression | White blood cells | Inventors | Medical prognosis | γ-Interferon | Mutation | Cancer | Tumors | Index Medicus | Immune Subtypes | Integrative Network Analysis | Cancer Genomics | Immuno-oncology | Tumor immunology
Journal Article
Annals of Oncology, ISSN 0923-7534, 04/2019, Volume 30, Issue 4, pp. 644 - 651
Abstract Background A nivolumab dosage regimen of 480 mg intravenously (i.v.) every 4 weeks (Q4W) was approved by FDA for the majority of the approved... 
nivolumab | ONCOLOGY |